AN IN VITRO TEST PREDICTIVE OF THE IN VIVO B CELL RITUXIMAB-TRIGGERED DEPLETION, UNDERLINES THE POTENTIAL THERAPEUTIC INTEREST OF A RECOMBINANT ANTI-CD20 IGA IN B-CLL PATIENTS

被引：0
|
作者：
Congy, N. [1 ]
Ysebaert, L. [2 ]
Apoil, P. [1 ]
Tiraby, G. [3 ]
Drocourt, D. [3 ]
Abbal, M. [1 ]
Blancher, A. [1 ]
机构：
[1] Univ Paul Sabatier, EA 3O34, Toulouse, France
[2] CHU Purpan, INSERM, U563, Toulouse, France
[3] Cayla Invivogen, Toulouse, France
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2010年 / 95卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1263
引用
收藏
页码：515 / 515
页数：1
相关论文
共 50 条
  • [31] Complement-dependent cytotoxicity exerted by two therapeutic anti-CD20 mAbs: Rituximab and ofatumumab in human B-cell malignant cell lines and primary cultures
    Okroj, M.
    Eriksson, I.
    Osterborg, A.
    Blom, A.
    MOLECULAR IMMUNOLOGY, 2013, 56 (03) : 292 - 292
  • [32] Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis
    Golay, J
    Zaffaroni, L
    Vaccari, T
    Lazzari, M
    Borleri, GM
    Bernasconi, S
    Tedesco, F
    Rambaldi, A
    Introna, M
    BLOOD, 2000, 95 (12) : 3900 - 3908
  • [33] Biological response of B lymphoma cell lines to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement mediated lysis.
    Golay, J
    Zaffaroni, L
    Vaccari, T
    Borleri, GM
    Tedesco, F
    Dastoli, G
    Barbui, T
    Rambaldi, A
    Introna, M
    BLOOD, 1999, 94 (10) : 92A - 92A
  • [34] A novel platform for RIT:: Extracorporeal depletion of biotinylated and 90Y-labeled anti-CD20 in patients with refractory B-cell lymphoma
    Tennvall, J
    Lindèn, O
    Kurkus, J
    Garkavij, M
    Cavallin-Stâhl, E
    Ljungberg, M
    Nilsson, R
    Ohlsson, T
    Sandberg, B
    Strand, SE
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2004, 19 (04) : 527 - 527
  • [35] Experimental therapeutic approach of human diffuse large B-cell lymphoma xenografts by doxycycline, alone or in combination with the anti-CD20 chimeric monoclonal antibody rituximab
    Assayag, F.
    Brousse, N.
    Couturier, J.
    Macintyre, E.
    Mathiot, C.
    De Plater, L.
    Dewulf, S.
    Vincent-Salomon, A.
    Poupon, M. F.
    Decaudin, D.
    EJC SUPPLEMENTS, 2008, 6 (12): : 26 - 26
  • [36] Toxicity and efficacy of the anti-CD20 antibody rituximab (Rituxan™) in patients with B-cell chronic lymphocytic leukemia:: A phase I/II study.
    Winkler, U
    Schulz, HR
    Jensen, M
    Manzke, O
    Rüdiger, T
    Müller-Hermelink, KH
    Diehl, V
    Engert, A
    BLOOD, 1999, 94 (10) : 312A - 312A
  • [37] AME-133v, a humanized, Fc-engineered anti-CD20 monoclonal antibody, demonstrates greater B cell depletion than Rituxan in vitro
    Wayne, Jennifer L.
    Campbell, Mary-Ann
    Marulappa, Shashi
    Jain, Vinay
    CANCER RESEARCH, 2012, 72
  • [38] Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation
    Beers, Stephen A.
    Chan, Claude H. T.
    James, Sonya
    French, Ruth R.
    Attfield, Kathrine E.
    Brennan, Claire M.
    Ahuja, Anupama
    Shlomchik, Mark J.
    Cragg, Mark S.
    Glennie, Martin J.
    BLOOD, 2008, 112 (10) : 4170 - 4177
  • [39] An afucosylated anti-CD20 monoclonal antibody with greater antibody-dependent cellular cytotoxicity and B-cell depletion and lower complement-dependent cytotoxicity than rituximab
    Gasdaska, John R.
    Sherwood, Steven
    Regan, Jeffrey T.
    Dickey, Lynn F.
    MOLECULAR IMMUNOLOGY, 2012, 50 (03) : 134 - 141
  • [40] A novel platform for radioimmunotherapy.: Extracorporeal depletion of biotinylated and 90Y-labeled anti-CD20 in patients with refractory B-cell lymphoma
    Tennvall, JG
    Lindén, O
    Garkavij, M
    Kurkus, J
    Cavallin-Ståhl, E
    Ohlsson, T
    Nilsson, R
    Sandberg, B
    Ljungberg, M
    Strand, SE
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2004, 31 : S221 - S221
12345